Capecitabine tablets build momentum for company's transparent business model; goal to create significant savings for patients, health system
Potential savings of $1,500/month compared with other generic versions
CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of its generic capecitabine. Capecitabine is a nucleoside metabolic inhibitor indicated for certain types of colorectal, breast, gastric, esophageal, gastroesophageal junction or pancreatic cancer. Specific information about the use of capecitabine can be found here.
https://mma.prnewswire.com/media/2625282/CivicaScript_Logo.jpg
CivicaScript will offer capecitabine 500 mg film-coated tablets for sale to pharmacies for $63 per bottle of 120 tablets. CivicaScript recommends that pharmacies charge patients no more than $84 per bottle (CivicaScript's maximum retail price, or MaxRPTM policy). CivicaScript will offer the 150 mg and 500 mg strengths of capecitabine tablets for sale.
CivicaScript's MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label.
CivicaScript's MaxRP forcapecitabine 500 mg tablets isabout$1,500 permonthlessthantheaverage claim costforprescriptions filled at traditional PBM-affiliated pharmacies.1It could significantly reduce patients' out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines' price.
“The momentum we're creating with our transparent business model is proving to be both successful and sustainable,” said CivicaScript President Brent J. Eberle. “We're aligning all stakeholders to prioritize the lowest sustainable cost, which means lower prices for patients and cost savings throughout the system.”
A recent report in The New England Journal of Medicine Catalyst showed that CivicaScript's first product, abiraterone, saved consumers 64% and payers 92% when they switched from other versions of the same drug.
CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript's business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing – with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient.
Capecitabine waschosenbyCivicaScriptmembersasaprioritygeneric medicinebasedonits high list price from other manufacturers and significant patient need for the product.
While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studiesconfirmthatmedicationcostscandictate whetherpatientsration theirprescriptionsor even fill them in the first place.
About CivicaScriptCivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A nonprofit company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit our website. CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency.
AboutcapecitabineFor full prescribing information and patient information, including warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert available here.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
MEDIA CONTACT:Liz Powerliz.power@civicarx.org+1 860 501 3849
1Compared with 2021 average commercial reimbursement rate for all strengths of capecitabine. See Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers, Federal Trade Commission Second Interim Staff Report, January 2025, at Fig. A2, Table A (pg. 34), available at https://www.ftc.gov/system/files/ftc_gov/pdf/PBM-6b-Second-Interim-Staff-Report.pdf
https://c212.net/c/img/favicon.png?sn=NY32080&sd=2025-07-17
View original content to download multimedia:https://www.prnewswire.com/news-releases/civicascript-launches-low-cost-cancer-drug-to-make-treatment-more-affordable-302507654.html
SOURCE CivicaScript
https://rt.newswire.ca/rt.gif?NewsItemId=NY32080&Transmission_Id=202507170930PR_NEWS_USPR_____NY32080&DateId=20250717